HCV protease drug race heats up as Vertex's telaprevir gains priority review in US and Canada
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals said that both the US FDA and Health Canada have accepted submissions for its hepatitis C drug telaprevir, and that priority review status has been granted.